Results 151 to 160 of about 106,089 (259)

The Future of Interventional Keratoconus Management: Perspectives on Integrating Epithelium-on Oxygen-Enriched Cross-Linking into Comprehensive Care Pathways. [PDF]

Ther Clin Risk Manag
Beckman KA, Syed ZA, Gromacki SJ.
europepmc   +1 more source

The role of pain in Graves' orbitopathy: Associations with clinical activity and quality of life

Acta Ophthalmologica, EarlyView.
Abstract Purpose Pain is included in the clinical activity score (CAS) as an indicator of inflammatory activity in Graves' orbitopathy (GO), yet its clinical relevance has not been systematically evaluated. We therefore investigated the relationship between pain, other inflammatory signs and quality of life (QoL), and assessed the effect of intravenous
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, Marco Medici, Maaike de Bie, P. Martin van Hagen, Dion Paridaens   +7 more
wiley   +1 more source

Message from the President

Vision Pan-America, 2013
Paulo E.C. Dantas
doaj   +1 more source

Peripheral nodulocystic corneal degeneration: a case report. [PDF]

Am J Ophthalmol Case Rep
Arino M, Lee M, Chong J, Yung M.
europepmc   +1 more source

Chlorhexidine 0.02% or polyhexamethylene biguanide 0.02% as the main treatment for Acanthamoeba keratitis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To report medical cure and treatment failure rates of Acanthamoeba keratitis (AK) with respect to type of treatment, disease stage and prognostic factors. Methods Electronic records were reviewed for 45 patients with PCR‐positive AK treated at the Department of Ophthalmology, Aarhus University Hospital, Denmark from 2012 to 2025 ...
Anders Ivarsen, Sandra M. Skovdal, Stine Elkjær Nielsen, Christen Rune Stensvold, Henrik Vedel Nielsen, Jesper Hjortdal   +5 more
wiley   +1 more source

Corneal Innervation Research at a Crossroads: A Tool-Driven Roadmap for the Future. [PDF]

Invest Ophthalmol Vis Sci
Matynia A, Meng ID, Davis BM, Pflugfelder SC, Galor A, Perez VL, Felix ER, Hamrah P, Rompolas P, Ruiz-Lozano RE, Bhuiyan SA, Moghbeli K, Semizoglou E, Renthal W, Singh H, Das J, Golczak M, Stepp MA, Morgans CW, de Paiva CS, Saab CY, Spigelman I, Sayegh RR, Largent-Milnes TM, Wu H, Luo W, Mitra S, Yoo H, Farsiu S, Littleton S, Jacob E, McPheeters MT, Lapierre-Landry M, Smith JJ, Wang X, Florea R, Widjaja-Adhi MAK, Holmes S, Zemborain Z, Laise KET, Pondelis NJ, Jeong KS, Chen R, Jenkins MW, Lee V, Moulton EA, Jacobs DS, Aicher SA, St Leger AJ, Saban DR.   +49 more
europepmc   +1 more source

Childhood ocular safety after postnatal exposure to topical dexamethasone during retinopathy of prematurity screening

Acta Ophthalmologica, EarlyView.
Abstract Purpose Dexamethasone eye drops are being introduced off‐label to prevent progression of severe retinopathy of prematurity (ROP). We evaluated ophthalmologic outcomes in early childhood after postnatal topical dexamethasone exposure in pre‐term infants at a standardized follow‐up examination.
Mariya Petrishka‐Lozenska, Anders K. Nilsson, Ann Hellström, Pia Lundgren   +3 more
wiley   +1 more source

Editorial

Vision Pan-America, 2012
Paulo E.C. Dantas
doaj   +1 more source

Special Issue "Integrated Approaches, Molecular Mechanisms and Therapies in Ocular Surface Diseases". [PDF]

Int J Mol Sci
Zeppieri M, Toro MD, Gagliano C.
europepmc   +1 more source

Three years of ocular proton therapy in the Netherlands, clinical results

Acta Ophthalmologica, EarlyView.
Abstract Purpose Uveal melanoma (UM) is a rare cancer with rising number of diagnosis (143 diagnoses in 1990 to 226 in 2023) in the Netherlands. Most patients are treated locally with Ruthenium‐106 brachytherapy (±102/year). Patients were referred for proton therapy (PT) to Switzerland in the past, but PT is available in the Netherlands from January ...
C. Rasch, M. Marinkovic, L. Pors, E. Kilic, N. Naus, S. Yavuzyigitoglu, P. A. Bakker, C. van Rij, J. W. Beenakker, J. Bleeker, A. Schalenbourg, A. Pica, J. Hrbacek, N. Horeweg, K. Vu   +14 more
wiley   +1 more source